Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986020 and Rosuvastatin PK Interaction Study
NCT02101125Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bms-986020 in idiopathic pulmonary fibrosis (IPF) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of Rosuvastatin, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of Rosuvastatin and 1 more. Started Mar 2014; status: completed.
02
Drugs
bms-986020
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02101125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101125.